Moleculin Biotech shares surge 10.56% intraday after positive Phase 1 trial results for WP1066 in pediatric brain tumors.

Moleculin Biotech, Inc. (MBRX) surged 10.56% intraday trading following the announcement that the pivotal “MIRACLE” Phase 3 AML trial has completed treatment for 45 patients, aligning with its Q1 2026 timeline. The company also reported positive results from a Phase 1 trial of WP1066 for pediatric recurrent malignant brain tumors and secured a new collaboration for Annamycin in brain tumor research. These developments, combined with recent patent expansions and global trial expansions, underscored investor confidence in Moleculin’s clinical pipeline and therapeutic potential, driving the intraday rally.